A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if belatacept (BMS-224818) is
expected to show acceptable rates of acute rejection (AR) in steroid-free belatacept-based
immunosuppressive regiments compared to a similar steroid-free tacrolimus regimen. The
long-term safety and tolerability of belatacept based regimens following long-term
administration in subjects who have received a kidney transplant